Literature DB >> 28271173

Vascularity and Tumor Size are Significant Predictors for Recurrence after Resection of a Pancreatic Neuroendocrine Tumor.

Yusuke Yamamoto1, Yukiyasu Okamura2, Sunao Uemura2, Teiichi Sugiura2, Takaaki Ito2, Ryo Ashida2, Yoshiyasu Kato2, Katsuhisa Ohgi2, Mihoko Yamada2, Keiko Sasaki3, Takeshi Aramaki4, Katsuhiko Uesaka2.   

Abstract

BACKGROUND: It is difficult to identify patients at high risk of recurrence after pancreatectomy for pancreatic neuroendocrine tumor (PNET) using only the grading classification, especially the G2 category, which includes both benign and low- and high-grade malignant tumors.
METHODS: Forty-one patients with PNET who underwent pancreatectomy were enrolled in this study. We defined the computed tomography (CT) ratio as the CT value of the tumor divided by that of non-tumorous pancreatic parenchyma using the late arterial phase dynamic CT. The optimal cut-off values for CT ratio and tumor size were determined using p-values that were calculated using the log-rank test.
RESULTS: The optimal cut-off values of CT ratio and tumor size for dividing patients into groups according to the greatest difference in disease-free survival (DFS) were 0.85 (p < 0.001) and 3.0 cm (p < 0.001), respectively. In analysis using Spearman's correlation coefficient, CT ratio (p = 0.007) and tumor size (p = 0.003) were individually associated with the Ki-67 proliferative index. Cox proportional hazard analysis identified that a CT ratio <0.85 (n = 10, p = 0.006) and tumor size ≥3.0 cm (n = 13, p = 0.023) were independent prognostic factors associated with DFS. All patients in the CT ratio ≥0.85 and tumor size <3.0 cm group (n = 23, including seven patients with G2 disease) did not develop recurrence after surgery. On the other hand, 5-year DFS in the CT ratio <0.85 and tumor size ≥3.0 cm group (n = 5, including three patients with G2 disease) was zero.
CONCLUSIONS: PNETs with a CT ratio <0.85 and tumor size ≥3.0 cm should be considered as having a high risk of recurrence after pancreatectomy.

Entities:  

Mesh:

Year:  2017        PMID: 28271173     DOI: 10.1245/s10434-017-5823-5

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  8 in total

Review 1.  Prognostic and predictive factors on overall survival and surgical outcomes in pancreatic neuroendocrine tumors: recent advances and controversies.

Authors:  Lingaku Lee; Tetsuhide Ito; Robert T Jensen
Journal:  Expert Rev Anticancer Ther       Date:  2019-11-27       Impact factor: 4.512

2.  Clinicopathological Characteristics of Nonfunctional Pancreatic Neuroendocrine Neoplasms and the Effect of Surgical Treatment on the Prognosis of Patients with Liver Metastases: A Study Based on the SEER Database.

Authors:  Abuduhaibaier Sadula; Gang Li; Dianrong Xiu; Chen Ye; Siqian Ren; Xin Guo; Chunhui Yuan
Journal:  Comput Math Methods Med       Date:  2022-05-12       Impact factor: 2.809

3.  Risk and prognostic nomograms for colorectal neuroendocrine neoplasm with liver metastasis: a population-based study.

Authors:  Xueliang Ding; Shaobo Tian; Jia Hu; Guobin Wang; Xiangnan Yu; Daan Fu; Ye Yuan; Lin Wang; Zheng Wang
Journal:  Int J Colorectal Dis       Date:  2021-06-01       Impact factor: 2.571

4.  Dynamic Enhancement Pattern on CT for Predicting Pancreatic Neuroendocrine Neoplasms with Low PAX6 Expression: A Retrospective Observational Study.

Authors:  Koichiro Kimura; Junichi Tsuchiya; Yoshio Kitazume; Mitsuhiro Kishino; Keiichi Akahoshi; Atsushi Kudo; Shinji Tanaka; Minoru Tanabe; Ukihide Tateishi
Journal:  Diagnostics (Basel)       Date:  2020-11-09

5.  Predicting the recurrence risk of pancreatic neuroendocrine neoplasms after radical resection using deep learning radiomics with preoperative computed tomography images.

Authors:  Chenyu Song; Mingyu Wang; Yanji Luo; Jie Chen; Zhenpeng Peng; Yangdi Wang; Hongyuan Zhang; Zi-Ping Li; Jingxian Shen; Bingsheng Huang; Shi-Ting Feng
Journal:  Ann Transl Med       Date:  2021-05

6.  Prediction of Pancreatic Neuroendocrine Tumor Grading Risk Based on Quantitative Radiomic Analysis of MR.

Authors:  Wei Li; Chao Xu; Zhaoxiang Ye
Journal:  Front Oncol       Date:  2021-11-17       Impact factor: 6.244

7.  Reconsideration of Clinicopathologic Prognostic Factors in Pancreatic Neuroendocrine Tumors for Better Determination of Adverse Prognosis.

Authors:  Anil Aysal; Cihan Agalar; Tufan Egeli; Tarkan Unek; Ilhan Oztop; Funda Obuz; Ozgul Sagol
Journal:  Endocr Pathol       Date:  2021-07-20       Impact factor: 3.943

8.  The latest exploration of staging and prognostic classification for pancreatic neuroendocrine tumors: a large population-based study.

Authors:  Shanshan Gao; Ning Pu; Lingxiao Liu; Changyu Li; Xuefeng Xu; Xiaolin Wang; Wenhui Lou
Journal:  J Cancer       Date:  2018-04-19       Impact factor: 4.207

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.